39 research outputs found
Autologous bone marrow transplantation contributes to haemopoietic recovery in children with solid tumours treated with high dose melphalan
No full textCOMPLETE REMISSION DURATION AND LONG-TERM SURVIVORS (LTS) IN CHRONIC MYELOGENOUS LEUKABMIA (CML): A THEORETICAL APPROACH TO A CLINICAL DECISION
No full text
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
No full textLight chain restriction analysis of bone marrow plasma cells in patients with MGUS or ‘solitary’ plasmacytoma: diagnostic value and correlation with clinical course
No full textSevere cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia.
No full textWe describe four patients who developed severe thrombocytopenia which progressed to aplasia after the use of alpha-interferon in maintenance therapy of chronic phase CML after busulphan induction. On reviewing over 400 patients in the MRC CML III trial we found that there is a risk of cytopenia developing after busulphan therapy and a lesser risk of cytopenias developing after alpha-interferon therapy. If the therapies are given in a sequential fashion the risk of cytopenia developing appears to be additive, may be pronounced, and may lead to clinically significant problems. Hydroxyurea alone does not lead to sustained cytopenia. Care should be taken to ensure that counts are stable after the use of busulphan before starting alpha-interferon as maintenance therapy
A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro
No full textSevere cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia
No full textThe Proliferative State of Clonogenic Cells In the Lewis Lung Tumour After Treatment With Cytotoxic Agents
No full text
